

Cite this: *RSC Adv.*, 2017, 7, 48025

DNA methylation differences of the *BPI* promoter among pig breeds and the regulation of gene expression†

HaiFei Wang,^a Jiayun Wu,^a Sen Wu,^a ShengLong Wu^{ab} and WenBin Bao^{ID} *^{ab}

The bactericidal/permeability-increasing protein (BPI) exerts broad-spectrum bactericidal effects against Gram-negative bacteria and contributes to natural defenses. The expression patterns of *BPI* among different pig breeds and the underlying regulatory mechanisms remain elusive. In this study, we presented that the pig breeds of Yorkshire, Sutan and Meishan showed distinct *BPI* expression and promoter DNA methylation patterns. The promoter methylation level in Yorkshire pigs was significantly higher than that in Meishan pigs ($P < 0.05$), while the gene expression level displayed a reverse trend. Correlation analyses revealed a strong negative correlation between *BPI* promoter methylation and mRNA expression. Luciferase assay indicated that DNA methylation of *BPI* promoter can result in the reduction of *BPI* transcriptional activity *in vitro*. Furthermore, animals differing in *E. coli* F18 susceptibility showed that sensitive individuals had significantly higher promoter methylation and lower gene expression levels than those of resistant individuals ($P < 0.05$). Our study showed distinct *BPI* promoter methylation and gene expression patterns among different pig breeds, and provided evidence for the potential link between *BPI* promoter methylation, *BPI* expression and disease susceptibility. The findings bring us a step forward towards the understanding of regulatory mechanisms underlying *BPI* expression and provide fundamental information for further studies on elucidating the contribution of *BPI* to intestinal immunity.

Received 17th May 2017
Accepted 8th October 2017

DOI: 10.1039/c7ra05549h

rsc.li/rsc-advances

Introduction

Bactericidal/permeability-increasing protein (BPI) is an anti-bacterial protein that is mainly secreted by neutrophils. *BPI* has several known biological functions, such as the ability to kill Gram-negative bacteria, neutralize free lipopolysaccharide, inhibit angiogenesis and the release of inflammatory mediators, and to reduce endotoxemia.^{1,2} The pig *BPI* protein has been shown to improve the resistance of pigs to *Escherichia coli* (*E. coli*) infection³ and neutralize endotoxins as well as kill Gram-negative bacteria.⁴ Balakrishnan *et al.* reported that injection of recombinant *BPI* protein could significantly attenuate endotoxemia caused by acute lung injury in pigs.⁵ The Meishan pigs and European pigs demonstrated pronounced discrepancies in the resistance to pathogenic infections including bacteria and viruses.^{6,7} In addition, Meishan and Large White pigs differed in innate immune traits including

neutrophil, monocyte and lymphocyte counts.⁶ Thus the *BPI* gene could be an interesting candidate to interpret the variability of resistance of pigs to bacterial infection.

DNA methylation is an epigenetic modification that is associated with various biological processes such as embryonic development, transcriptional regulation of a gene, genomic imprinting and inflammation.⁸ DNA methylation is stably inherited *via* cell division, and thus represents a major epigenetic modification.⁹ It is known that promoter methylation can repress the expression of genes by influencing the binding of transcription factors.¹⁰ Furthermore, we previously reported that promoter CpG island methylation of the *BPI* gene was negatively associated with the expression of this gene in the Sutan pigs.¹¹ However, the functional consequences of *BPI* promoter methylation have not been illuminated.

The objectives of this study were to identify whether the *BPI* promoter exhibits distinct DNA methylation patterns in different pig breeds, and elucidate the molecular mechanisms underlying *BPI* expression. We measured the DNA methylation levels of *BPI* promoter in Meishan, Yorkshire and Sutan (Duroc × Taihu intercross) pig breeds. We have also performed functional analysis of the relationship between *BPI* promoter methylation and *BPI* expression. In addition, we explored the potential link between *BPI* promoter methylation, *BPI* expression in animals differing in disease susceptibility.

^aKey Laboratory for Animal Genetics, Breeding, Reproduction and Molecular Design of Jiangsu Province, College of Animal Science and Technology, Yangzhou University, Yangzhou 225009, China. E-mail: wbbao@yzu.edu.cn

^bJoint International Research Laboratory of Agriculture & Agri-Product Safety, Yangzhou University, Yangzhou 225009, Jiangsu, China

† Electronic supplementary information (ESI) available. See DOI: 10.1039/c7ra05549h



Experimental

Ethics statement

The animal study proposal was approved by the Institutional Animal Care and Use Committee (IACUC) of the Yangzhou University Animal Experiments Ethics Committee (permit number: SYXK (Su) IACUC 2012-0029). All experimental procedures were performed following the Regulations for the Administration of Affairs Concerning Experimental Animals approved by the State Council of the People's Republic of China.

Animals and sample collection

The three pig breeds of Chinese domestic Meishan pigs, Western commercial Yorkshire pigs and hybrid Suta (Duroc × Taihu) pigs ($n = 5$ per breed) at 35 days old were obtained from our three experimental farms, Changzhou Kangle Farming Co., Ltd. (National core pig breeding farm), Suta Pig Breeding Center in Suzhou City of Jiangsu Province and Meishan Pig Conservation Breeding Company of Kunshan City, respectively. To circumvent the potential impacts of environmental factors such as feed type, weaning age and vaccination usage, the farms adopted the same feeding procedures for these individuals. The animals were allowed access to feed and water, and humanely sacrificed *via* intravenous injection of sodium pentobarbital. As representing the largest compartment of the immune system and being the main site for adhesion and colonization of enterotoxigenic *E. coli*,^{12,13} the small intestine was collected and used for subsequent analyses. In addition, we previously performed transcriptomic and proteomic analyses of the duodenum section which is one of the important sites of *E. coli* F18 strain colonization and replication.^{14–16} To extend our previous findings and better elucidate the molecular mechanisms underlying *E. coli* F18 infection, the duodenum section of the intestine was thus used in this study. The distal part of duodenum (approximately 2 cm circle segments) was collected and rinsed with phosphate buffer saline, and then placed in 1.5 mL nuclease-free tubes, immediately snap-frozen in liquid nitrogen and stored at -80°C until analysis.

In addition, six duodenum samples obtained from three pairs of Suta pigs differing in *E. coli* F18 susceptibility were also used in this study. The *E. coli* F18 susceptibility was defined by the adherence assays, in which the animals whose intestinal epithelial cells showed nearly no adherence with *E. coli* F18 were defined as the resistant individuals, and those showed clear adherence were defined as the susceptible individuals. Verification of the susceptibility to *E. coli* F18 by the type V secretion system and collection of the duodenum samples have been described in our previous study.¹⁴

Bioinformatic analysis of *BPI* promoter

The 3 kb sequences (chr17: 41356468–41359467) upstream of the *BPI* gene were downloaded from the Ensembl database and analyzed for CpG island identification. CpG island was predicted using the online MethPrimer program¹⁷ and defined as the DNA regions greater than 100 bp with a C + G content equal to or greater than 50% and an observed CpG/expected CpG in

excess of 0.6. Potential transcription factor binding sites (TFBS) within the CpG island were identified using the online tool AliBaba 2.1 (<http://www.gene-regulation.com/pub/programs/alibaba2/index.html>).

Normal DNA PCR products sequencing

Genomic DNA was extracted from porcine duodenal tissues by standard phenol/chloroform method. The DNA sequence of a 489 bp fragment containing the CpG island was amplified to screen for single nucleotide polymorphisms (SNPs) in all individuals. PCR primer sequences are provided in ESI Table S1.† The PCR system contained 1.0 μL template DNA, 2 μL PCR buffer (10 \times), 0.8 μL dNTPs (10 mM), 2.2 μL Mg^{2+} (25 mM), 1.0 μL (10 μM) of each primer, 0.2 μL Taq DNA polymerase (5 U μL^{-1}) and 12.8 μL sterilized distilled water. The PCR protocol was 5 min initial denaturation at 95°C , followed by 40 cycles of 30 s at 95°C , 30 s at 53°C , 30 s at 72°C , and a final extension step of 10 min at 72°C . The PCR products were checked by electrophoresis in 1% agarose gels and sequenced by Invitrogen (Shanghai, China). The sequences were aligned to the pig reference genome (*Sus scrofa* 10.2) for SNP identification using the software BLAST (<https://blast.ncbi.nlm.nih.gov/Blast.cgi>).

Bisulfite sequencing PCR methylation analysis

Genomic DNA was subjected to bisulfite conversion using the EpiTect bisulfite kit (Qiagen, Valencia, CA, USA) following the manufacturer's instructions. PCR assays were performed to amplify the bisulfite-treated DNA. The PCR primer sequences are provided in ESI Table S1.† The 50 μL reactions included 3 μL DNA template, 3 μL 10 \times PCR buffer, 2 μL Mg^{2+} (25 mmol L^{-1}), 1 μL forward and reverse BSP primer (10 μM L^{-1}), 1 μL dNTPs (10 mmol L^{-1}), 0.8 μL Taq polymerase (5 U μL^{-1}) and 38.2 μL distilled deionized water. The following reaction conditions were used: 98°C for 4 min, then 20 cycles of 94°C for 45 s, 66°C for 45 s (reduced by 0.5°C with each cycle) and 72°C for 1 min; 20 cycles of 94°C for 45 s, 56°C for 45 s and 72°C for 1 min, with a final extension at 72°C for 10 min. The products (195 bp) were electrophoresed on 1% agarose gels and purified with TIANquick Midi purification kit (Tiangen Biotech, Beijing) according to the manufacturer's protocols. Purified PCR products were then cloned into the pMD18-T vector (Takara, Dalian, China) following the manufacturer's guidelines. Colony PCR assays were performed for the identification of positive clones. A total of 10–20 positive clones for each sample were randomly selected for sequencing (Invitrogen Biotechnology, Shanghai, China). The bisulfite sequence data for CpG methylation level were analyzed by quantification tool for methylation analysis (QUMA) software.¹⁸

Luciferase assays

The 1195 bp (chr17: 41357119–41358313) of *BPI* promoter sequences including the CpG island and 500 bp of upstream and downstream sequences were cloned into a CpG-free luciferase reporter vector kindly provided by Dr Klug and Dr Rehli.¹⁹ The sequence with SpeI and NcoI restriction sites was synthesized by Invitrogen Biotechnology (Shanghai, China). The sequence was then ligated into the CpG-free vector between



SpeI-NcoI sites and transformed into BW23473 competent cells for plasmid construction. The constructs were treated with DNA methyltransferase SssI (NEB, Beijing, China) to methylate all cytosine residues at CpG sites. The methylated constructs were purified by TIANquick Midi purification kit (Tiangen Biotech, Beijing) according to the manufacturer's protocols and quantified using a Nanodrop Spectrophotometer (Thermo Scientific, Wilmington, USA). IPEC-J2 cells were co-transfected with 100 ng CpG-free vector either with or without respective insert together with 2 ng of pRL-TK vector as an internal control reporter, using Lipofectamine 2000 (Invitrogen, Carlsbad, USA) in 96-well plates following the manufacturer's instructions. Luminescence was tested after 24 hours transfection using the dual-luciferase reporter assay system (Promega, Madison, USA) on a Tecan Infinite 200 microplate reader (Tecan, Switzerland).

Real-time PCR

Total RNA was extracted from the duodenal tissues using RNAiso Plus and reversely transcribed into cDNA using PrimerScript RT reagent Kit with gDNA Eraser (TaKaRa, Dalian, China) following the manufacturer's protocols. The real-time PCR (RT-PCR) assay was performed in 20 μ L reaction mixtures containing 2 μ L (100 ng) cDNA, 0.4 μ L of each forward and reverse primer (10 μ mol L⁻¹), 10 μ L SYBR Green RT-PCR Master Mix (2 \times), 0.4 μ L ROX Reference Dye II (50 \times), and 6.8 μ L distilled deionized water. The RT-PCR reactions were amplified at 95 $^{\circ}$ C for 30 s, followed by 40 cycles of 95 $^{\circ}$ C for 5 s and 62 $^{\circ}$ C for 34 s. Each sample was tested in triplicate in three independent experiments to ensure the

reproducibility of the data. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an internal reference, and the $2^{-\Delta\Delta C_t}$ method was used to determine the mean relative expression levels of *BPI*.²⁰ All primers (ESI Table S1†) were synthesized by Invitrogen Biotechnology (Shanghai, China).

Statistical analyses

Statistical analyses were carried out using SPSS 15.0 software (SPSS Inc., Chicago, IL, USA). The *BPI* promoter methylation and gene expression levels of five individuals in each breed were averaged respectively. To analyze the statistical significance of differences in methylation level and mRNA expression among the three breeds, the least significant difference (LSD) method was performed to determine the significance at a 5% significance level. Pearson's correlation was conducted to analyze the associations between *BPI* promoter methylation and gene expression levels, and the significance level was set at 5%.

Results

Identification of CpG island and transcription factor binding sites in the *BPI* promoter

One CpG island located in chr17: 41357619-41357813 was identified in the 3 kb sequence upstream of the *BPI* gene (ESI Fig. S1†). Five putative transcription factor binding sites (TFBS) were predicted in the CpG island (ESI Fig. S2†), of which the sites for transcription factors AP-2, NF-1 and Pax-3 contained CpG sites.




Fig. 1 Methylation levels of the individual CpG sites (A) and mRNA expression of the *BPI* gene (B) in the duodenum of different pig breeds. Bars indicate means \pm standard deviation ($N = 5$). * $P < 0.05$, ** $P < 0.01$.






Fig. 2 Relationship between *BPI* gene relative mRNA expression and promoter CpG island methylation levels in the duodenum of three pig breeds.

Verification of the PCR products of normal DNA and bisulfite-modified DNA

The PCR products were checked by 1% gel electrophoresis (ESI Fig. S3†). The sizes of PCR products had expected length (489 bp and 195 bp) and the product bands were specific, indicating that the PCR products could be used for subsequent analysis.

SNPs identification, CpG methylation and *BPI* expression

The PCR products of a 489 bp fragment containing the CpG island for all individuals were sequenced using Sanger sequencing. After alignment to the pig reference genome, no SNPs were identified within the sequence. The CpG methylation levels of each CpG site within the CpG island are presented in Fig. 1A. The methylation levels of CpG-1, CpG-2, CpG-3, CpG-6, CpG-7 and CpG-10 in Yorkshire pigs were significantly higher than in Meishan pigs ($P < 0.05$). The *BPI* expression level was significantly lower in Yorkshire pigs than in Meishan pigs ($P < 0.05$, Fig. 1B).

Correlation between expression of *BPI* and the overall methylation level of the CpG island

Bisulfite sequencing PCR revealed a strong negative correlation ($R = -0.8125$, $r_{0.01} = 0.64$, $r_{0.01}$ is the correlation coefficient threshold) between expression of the *BPI* gene and the overall methylation status of the CpG island in the *BPI* promoter region




Fig. 3 Relationship between the relative expression of *BPI* mRNA and the methylation levels of the CpG sites in the duodenum of different pig breeds. For Pearson's correlation analysis, r_α is the correlation coefficient threshold and α is the significant factor, where $\alpha = 0.05$ means the significant correlation level and $\alpha = 0.01$ represents the extremely significant correlation level.




Fig. 4 Analysis of the effects of *BPI* promoter methylation on transcriptional activity. Bars represent mean \pm standard deviation ($N = 3$). $*P < 0.05$.

in duodenum across the three pig breeds. Moreover, the mRNA expression level of *BPI* ranged from low to high in Yorkshire, Sutai and Meishan pigs, whereas the overall methylation status of *BPI* promoter CpG island exhibited an opposite trend (Fig. 2). The expression of *BPI* mRNA was significantly higher in Meishan pigs than in Yorkshire pigs ($P < 0.05$), while the overall methylation status of the CpG island was significantly lower in Meishan pigs than in Yorkshire pigs ($P < 0.05$).

Correlation between expression of *BPI* and methylation of individual CpG sites

The methylation status of all ten CpG sites in the CpG island of the *BPI* promoter was obtained. Pearson correlation analysis was performed to test the relationship between the methylation level of each CpG site and *BPI* expression. The results revealed a negative correlation between *BPI* expression and the methylation level of the ten CpG sites (Fig. 3). The CpG site methylation level in relation to *BPI* expression for each individual is shown in ESI Fig. S4.† The negative relationship was statistically significant for CpG-1, CpG-2, CpG-3, CpG-7, CpG-9 and CpG-10 ($P < 0.01$).

Functional analysis of *BPI* promoter CpG island methylation

Luciferase assays were conducted to functionally test if DNA methylation in *BPI* promoter regulates gene expression. The 1195 bp *BPI* promoter sequences were inserted into a CpG-free luciferase reporter vector that can be utilized to test the effects of CpG methylation on transcriptional activity of promoters. The constructed plasmid was methylated with DNA methyltransferase SssI or mock-methylated, and then transfected into IPEC-J2 cells for luciferase activity analysis. The results showed that methylation of the promoter sequences suppressed reporter gene expression to $28 \pm 10.6\%$ which was significantly lower than that of controls ($P < 0.05$, Fig. 4), indicating that increased DNA methylation level of *BPI* promoter can result in reduction of *BPI* transcriptional activity. Furthermore, we identified the *BPI* promoter methylation and mRNA expression in three pairs of Sutai pigs differing in *E. coli* F18 susceptibility. The results demonstrated that the DNA methylation level of *BPI* promoter was significantly higher in sensitive individuals than






Fig. 5 The *BPI* promoter methylation level (A) and *BPI* expression (B) in individuals differing in *E. coli* F18 susceptibility. Bars denote mean \pm standard deviation ($N = 3$). $*P < 0.05$.

in resistant individuals ($P < 0.05$, Fig. 5A), while the expression level of *BPI* was significantly lower in sensitive individuals ($P < 0.05$, Fig. 5B).

Discussion

In this study, we observed that the three pig breeds exhibited distinct DNA methylation patterns of *BPI* promoter methylation in duodenum. In addition, we provided evidence for the functional consequence of promoter methylation on *BPI* expression. Analyses of the individuals differing in *E. coli* F18 susceptibility further confirmed the negative relationship between *BPI* promoter methylation and mRNA expression and suggested a potential link between *BPI* promoter methylation, *BPI* expression and disease susceptibility.

As an important antibacterial protein, identification of the regulatory mechanisms underlying *BPI* expression will enable us to better understand the functional roles of *BPI* in antibacterial infection. It has been shown that overexpression of *BPI* significantly attenuates bacterially induced signaling,²¹ indicating the significance of expression regulation of the *BPI* gene. DNA methylation as one of the mechanisms for controlling gene expression provides a molecular means to elucidate the regulation of *BPI* expression. Moreover, our previous work revealed the negative relationship between *BPI* promoter methylation and its expression in duodenum of pigs.¹¹ Our functional analysis demonstrated that increased DNA methylation of *BPI* promoter resulted in the decrease of transcriptional activity *in vitro*, which provides further evidence for the negative relationship between *BPI* promoter methylation and gene expression. Nevertheless, variations in *BPI* promoter methylation whether have direct impacts on gene expression *in vivo* needs to be further investigated.

The variability in *BPI* expression between different breeds has been previously identified, while the underlying molecular mechanisms remain largely unknown. To better reflect the differences of *BPI* promoter methylation and gene expression among different pigs, three representative pig breeds of Meishan, Yorkshire and Sutan were used in this work. Here we unraveled the differences in *BPI* promoter

methylation pattern between the pigs of Meishan, Sutan and Yorkshire. Comparison analysis demonstrated Meishan pigs showed significantly lower methylation level and higher *BPI* expression than those of Yorkshire pigs. Given that DNA methylation status can be affected by environmental factors, the animals raised with the same feeding procedures were used to provide evidence for the link of these observed methylation differences with the pig breeds. In addition, the recent study has shown the breed-specific promoter methylation and mRNA expression of the glucocorticoid receptor gene between Large White and Erhualian pigs.²² Thus the breed differences may be an important factor influencing gene promoter methylation in the pig. Moreover, previous studies demonstrated that the variability in the gene specific methylation pattern is probably associated with the differences in prostate cancer susceptibility.^{23,24} Our analyses of *BPI* promoter specific methylation pattern in animals differing in *E. coli* F18 revealed that the resistant individuals exhibit lower methylation level and higher *BPI* expression, implicating the potential role of *BPI* promoter methylation in determining the susceptibility to bacterial infection.

It is an important pattern for methylated DNA to regulate gene expression by affecting transcription factor occupancy.²⁵ Transcription factor prediction analysis herein revealed that there are putative binding sites for the transcription factors AP-2 and Pax-3, which include CpG sites showing significantly negative associations between the methylation levels and *BPI* expression. Particularly, the binding site for AP-2 contained three CpG sites (CpG-1, CpG-2 and CpG-3) and that for Pax-3 contained one CpG site (CpG-9). It has been reported that CpG methylation can inhibit binding of AP-2 and thereby regulate proenkephalin gene expression.²⁶ In addition, DNA binding by Pax-3 was differentially influenced by methylation of the binding sites.²⁷ These indicated that methylation of these CpG sites may affect the binding of AP-2 and Pax-3 to the promoter region and thereby modulate *BPI* expression. However, functional analysis is required to unveil the potential molecular event underlying regulation of *BPI* expression by CpG methylation.



Conclusions

In summary, we demonstrated that differences exist in the promoter methylation status and mRNA expression of the *BPI* gene between different pig breeds and that DNA methylation plays a role in the regulation of the *BPI* mRNA expression. We further revealed the potential link between *BPI* promoter methylation, *BPI* expression and disease susceptibility. Our findings bring us a step forward to the understanding of regulatory mechanisms underlying the *BPI* gene expression and provide fundamental information for further studies on elucidating the contribution of *BPI* to intestinal immunity.

Competing interests

The authors declare that there are no competing interests.

Acknowledgements

We would like to thank the native English speaking scientists of Elixigen Company (Huntington Beach, California) for editing our manuscript. This research was supported by the National Key Technology R&D Program of the Ministry of Science and Technology (2015BAD03B01), the National Natural Science Funds (31372285, 31172183), and the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD).

References

- 1 D. W. van der Schaft, E. A. Toebes, J. R. Haseman, K. H. Mayo and A. W. Griffioen, *Blood*, 2000, **96**, 176–181.
- 2 H. Nishimura, A. Gogami, Y. Miyagawa, A. Nanbo, Y. Murakami, T. Baba and S. Nagasawa, *Immunology*, 2001, **103**, 519–525.
- 3 J. Weiss, G. Wright, A. C. Bekkers, C. J. Van Den Bergh and H. M. Verheij, *J. Biol. Chem.*, 1991, **266**, 4162–4167.
- 4 A. Chockalingam, C. E. McKinney, M. Rinaldi, D. S. Zarlega and D. D. Bannerman, *Vet. Microbiol.*, 2007, **125**, 80–90.
- 5 A. Balakrishnan, S. A. Marathe, M. Joglekar and D. Chakravorty, *Innate Immun.*, 2013, **19**, 339–347.
- 6 M. Clapperton, S. C. Bishop and E. J. Glass, *Vet. Immunol. Immunopathol.*, 2005, **104**, 131–144.
- 7 G. Reiner, J. Eckert, T. Peischl, S. Bocher, T. Jakel, U. Mackenstedt, A. Joachim, A. Dauschies and H. Geldermann, *Vet. Parasitol.*, 2002, **106**, 99–113.
- 8 C. Bock, *Nat. Rev. Genet.*, 2012, **13**, 705–719.
- 9 R. Lister, M. Pelizzola, R. H. Dowen, R. D. Hawkins, G. Hon, J. Tonti-Filippini, J. R. Nery, L. Lee, Y. Zhen, Q. M. Ngo, L. Edsall, J. Antosiewicz-Bourget, R. Stewart, V. Ruotti, A. H. Millar, J. A. Thomson, B. Ren and J. R. Ecker, *Nature*, 2009, **462**, 315–322.
- 10 H. Zhu, G. H. Wang and J. Qian, *Nat. Rev. Genet.*, 2016, **17**, 551–565.
- 11 J. Wang, X. M. Yin, L. Sun, S. Y. Sun, C. Zi, G. Q. Zhu, S. L. Wu and W. B. Bao, *Int. J. Mol. Sci.*, 2014, **15**, 10989–10998.
- 12 J. M. Fleckenstein, P. R. Hardwidge, G. P. Munson, D. A. Rasko, H. Sommerfelt and H. Steinsland, *Microbes Infect.*, 2010, **12**, 89–98.
- 13 A. M. Mowat and W. W. Agace, *Nat. Rev. Immunol.*, 2014, **14**, 667.
- 14 W. B. Bao, L. Ye, J. Zhu, Z. Y. Pan, Z. D. Du, G. Q. Zhu, X. G. Huang and S. L. Wu, *Anim. Genet.*, 2012, **43**, 525–534.
- 15 L. Ye, X. M. Su, Z. C. Wu, X. R. Zheng, J. Wang, C. Zi, G. Q. Zhu, S. L. Wu and W. B. Bao, *PLoS One*, 2012, **7**, e43741.
- 16 Z. C. Wu, R. W. Xia, X. M. Yin, Y. J. Huo, G. Q. Zhu, S. L. Wu and W. B. Bao, *PLoS One*, 2015, **10**, e0127164.
- 17 L. C. Li and R. Dahiya, *Bioinformatics*, 2002, **18**, 1427–1431.
- 18 Y. Kumaki, M. Oda and M. Okano, *Nucleic Acids Res.*, 2008, **36**, W170–W175.
- 19 M. Klug and M. Rehli, *Epigenetics*, 2006, **1**, 127–130.
- 20 K. J. Livak and T. D. Schmittgen, *Methods*, 2001, **25**, 402–408.
- 21 G. Canny, E. Cario, A. Lennartsson, U. Gullberg, C. Brennan, O. Levy and S. P. Colgan, *Am. J. Physiol.: Gastrointest. Liver Physiol.*, 2006, **290**, G557–G567.
- 22 Q. Sun, Y. Jia, R. Li, X. Li, X. Yang and R. Zhao, *Animal*, 2014, **8**, 1851–1856.
- 23 P. M. Das, K. Ramachandran, J. Vanwert, L. Ferdinand, G. Gopisetty, I. M. Reis and R. Singal, *Mol. Cancer*, 2006, **5**, 28.
- 24 K. Woodson, J. Hanson and J. Tangrea, *Cancer Lett.*, 2004, **205**, 181–188.
- 25 M. T. Maurano, H. Wang, S. John, A. Shafer, T. Canfield and K. Lee, *Cell Rep.*, 2015, **12**, 1184–1195.
- 26 M. Comb and H. M. Goodman, *Nucleic Acids Res.*, 1990, **18**, 3975–3982.
- 27 M. D. Galibert, U. Yavuzer, T. J. Dexter and C. R. Goding, *J. Biol. Chem.*, 1999, **274**, 26894–26900.

